Cancer Biomarkers

Cancer Biomarkers Market by Biomarker Type (Genetic, Protein), Cancer Type (Blood Cancer, Breast Cancer, Colorectal Cancer), Technology, Application, End User - Global Forecast 2024-2030

360iResearch Analyst
Want to know more about the cancer biomarkers market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[183 Pages Report] The Cancer Biomarkers Market size was estimated at USD 28.31 billion in 2023 and expected to reach USD 31.23 billion in 2024, at a CAGR 10.71% to reach USD 57.75 billion by 2030.

Cancer Biomarkers Market
To learn more about this report, request a free PDF copy

Cancer biomarkers are substances or processes that can be measured in parts of the body, such as blood or tissue, and help to detect the presence of cancer in the body. They can be proteins, genetic mutations, or other molecules that indicate the body may be fighting cancer. The use of cancer biomarkers is expanding primarily due to advancements in technology, which improve the accuracy and speed of these tests. Moreover, growing awareness of personalized medicine, which tailors treatment to individual patients and improves outcomes, has increased the applications of cancer biomarkers. However, false positives or negatives in tests, which can lead to incorrect treatment decisions, may challenge the market growth. Nevertheless, developing biomarkers for types of cancers that are currently hard to detect early, such as pancreatic or ovarian cancer, may increase the scope of market expansion. Additionally, integrating biomarkers with digital health information systems could enhance patient monitoring and ongoing treatment adjustments.

Regional Insights

In the Americas, robust healthcare infrastructure and a high level of awareness about cancer screening and early detection drive the demand for cancer biomarkers. The region, especially the United States, is also home to numerous leading biotechnology and healthcare companies engaged in developing and commercializing new biomarkers. This marketplace benefits significantly from supportive government initiatives and substantial investment in research and development. EMEA also presents a substantial market for cancer biomarkers, supported by well-established healthcare systems in Western Europe and increasing government support for cancer research across the Middle Eastern and African countries. The Asia Pacific region showcases rapid growth in the cancer biomarkers field due to rising healthcare spending and the increasing prevalence of cancer. Countries such as China, Japan, and India are investing heavily in healthcare infrastructure and research, facilitating growth. Additionally, the expanding middle-class populations in these economies present a significant opportunity for the adoption of advanced healthcare solutions, including cancer biomarkers.

Biomarker Type: Usability of protein biomarkers in detecting the presence of cancer through proteins found in blood or tissue

Genetic biomarkers refer to specific sequences in DNA that can signal an increased risk of cancer or indicate the presence of cancer. For instance, certain mutations in genes, such as BRCA1 and BRCA2, are well-known genetic biomarkers for breast and ovarian cancers. Detecting these mutations can help in identifying individuals at higher risk, thus facilitating early intervention or more tailored treatment strategies. Protein biomarkers, on the other hand, are proteins found in blood or tissue that can also indicate the presence of cancer. These proteins can be either elevated or depressed in cancer patients compared to healthy individuals.

Application: Preferences for biomarkers in diagnostic for early-stage detection to improve treatment outcomes for patients

Biomarkers can be vital tools for diagnosing cancer, helping detect the disease at an early stage, or confirming a diagnosis based on specific biomarker levels in the body. This early detection significantly improves treatment outcomes for patients. In the realm of drug discovery, cancer biomarkers assist researchers in identifying which mechanisms should be targeted by new drugs, potentially speeding up the development process and improving the effectiveness of new therapies. They also serve as tools during clinical trials, helping to monitor how well a drug is working. Biomarkers are crucial in prognostics, as they help predict a similar course of cancer in an individual, determine how aggressive it is, and guide treatment decisions, including suitable therapy options and personalized treatment plans. Finally, in risk assessment, biomarkers can reveal the genetic predisposition of individuals to certain types of cancers, enabling earlier surveillance and preventive strategies to be implemented. This proactive approach leads to earlier intervention for specific risk profiles of the patient. By comprehensively understanding and implementing these applications, cancer biomarkers become indispensable tools in advancing the effectiveness and precision of cancer treatment and management.

Market Dynamics

The market dynamics represent an ever-changing landscape of the Cancer Biomarkers Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Cancer Biomarkers Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Cancer Biomarkers Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Cancer Biomarkers Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Cancer Biomarkers Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Cancer Biomarkers Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Cancer Biomarkers Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Cancer Biomarkers Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Cancer Biomarkers Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Cancer Biomarkers Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Cancer Biomarkers Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cancer Biomarkers Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cancer Biomarkers Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities

    ChromaCode, Inc. and the Department of Pathology at the Medical College of Georgia have announced a partnership aimed at evaluating the performance of ChromaCode's innovative HDPCR assay for non-small cell lung cancer (NSCLC). This assay, endorsed for its comprehensive coverage of clinically relevant variants by the National Comprehensive Cancer Network, delivers rapid results with a 4-hour workflow and utilizes cloud-based analytics for quick interpretation. [Published On: 2024-03-20]

  • Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics

    China-based XtalPi and CK Life Sciences are intensifying their joint efforts to utilize artificial intelligence (AI) to develop miRNA-based molecular diagnostic models tailored for postoperative cancer care. This collaboration aims to refine prognostic risk predictions by analyzing anonymized clinical data and biomarker information sourced from both cancer patients and healthy individuals within CK's extensive database. [Published On: 2023-11-06]

  • Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs

    The U.S. Food and Drug Administration (FDA) has introduced a pivotal pilot program focused on refining the integration of specific oncology drugs with their corresponding in-vitro diagnostic tests. This initiative primarily addresses the critical use of laboratory-developed tests (LDTs), which have yet to undergo the FDA's extensive review for safety or effectiveness. The program aims to establish and make public the minimum performance characteristics necessary for diagnostic tests utilized in clinical trials. [Published On: 2023-06-21]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cancer Biomarkers Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Agilent Technologies, Inc., ASURAGEN, INC., Bio-Rad Laboratories, Inc., bioMérieux SA, Bristol-Myers Squibb Company, Bruker Corporation, Charles River Laboratories International, Inc., Enzo Biochem, Inc., Epigenomics AG, Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hologic, Inc., Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., PerkinElmer, Inc., Pfizer Inc., QIAGEN N.V, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Cancer Biomarkers Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Cancer Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Biomarker Type
    • Genetic
    • Protein
  • Cancer Type
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Skin Cancer
    • Stomach Cancer
  • Technology
    • Bioinformatics
    • Cytogenetics
    • Imaging Technology
    • Immunoassays
    • OMICS Technology
  • Application
    • Diagnostics
    • Drug Discovery & Development
    • Prognostics
    • Risk Assessment
  • End User
    • Academic & Cancer Research Centers
    • Hospitals
    • Speciality Centers

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Cancer Biomarkers Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Cancer Biomarkers Market, by Biomarker Type
  7. Cancer Biomarkers Market, by Cancer Type
  8. Cancer Biomarkers Market, by Technology
  9. Cancer Biomarkers Market, by Application
  10. Cancer Biomarkers Market, by End User
  11. Americas Cancer Biomarkers Market
  12. Asia-Pacific Cancer Biomarkers Market
  13. Europe, Middle East & Africa Cancer Biomarkers Market
  14. Competitive Landscape
  15. Competitive Portfolio
  16. List of Figures [Total: 26]
  17. List of Tables [Total: 480]
  18. List of Companies Mentioned [Total: 25]
The Emergence of Better Biomarkers for the Detection of Aggressive Liver Cancer
August 29, 2023
The Emergence of Better Biomarkers for the Detection of Aggressive Liver Cancer
Cancer remains a major global health challenge that poses significant economic and social implications to society. Liver cancer is the most common cancer globally, and it is expected to continue increasing due to risk factors such as viral infections and unhealthy lifestyles. Early detection of liver cancer significantly improves patients' prognosis and survival rates. However, detecting liver cancer in its early stages has proved challenging due to the lack of effective and sensitive screening tests. Researchers have recently focused on identifying biomarkers that can accurately detect liver cancer to improve patient outcomes and ensure timely intervention. This blog will discuss the emergence of better biomarkers for detecting aggressive liver cancer.

What are Biomarkers?

Biomarkers are biological molecules that indicate a particular physiological or pathological condition in the body. Examples of biomarkers commonly used in cancer diagnosis include gene mutations, altered protein levels, and differences in the expression of RNA. Biomarker performance is measured by their sensitivity, specificity, and accuracy in diagnosing cancer.

Emerging Biomarkers for Aggressive Liver Cancer:

Recent technical advancements in genomic and proteomic technologies have enabled researchers to identify novel biomarkers that can accurately detect liver cancer in its early stages.

Circulating Tumor DNA:

The assessment of circulating tumor DNA (ctDNA) in the blood has emerged as a promising tool for early detection of liver cancer. Researchers have found that ctDNA in blood samples can detect early-stage liver cancer, making it a valuable diagnostic tool. Additionally, ctDNA can signal cancer recurrence after treatment, enabling clinicians to monitor disease progression and plan patient management.

Exosomal miRNAs:

Exosomes are small membrane-bound vesicles carrying cellular components, including proteins and nucleic acids and microRNAs (miRNAs). Exosomal miRNAs have been found to play a significant role in liver cancer development, progression, and metastasis.

Early detection of aggressive liver cancer is vital for improving patient survival. Recent developments in genetics and proteomics have identified novel biomarkers that accurately detect liver cancer in its early stages. These different biomarkers provide clinicians with a range of tools to diagnose and monitor liver cancer in patients. These new biomarkers hope to improve liver cancer diagnosis and treatment, ensuring timely intervention and improving patient outcomes.

Frequently Asked Questions
  1. How big is the Cancer Biomarkers Market?
    Ans. The Global Cancer Biomarkers Market size was estimated at USD 28.31 billion in 2023 and expected to reach USD 31.23 billion in 2024.
  2. What is the Cancer Biomarkers Market growth?
    Ans. The Global Cancer Biomarkers Market to grow USD 57.75 billion by 2030, at a CAGR of 10.71%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.